Skip to main content
. 2023 Jan 31;14(2):697–705. doi: 10.1002/jcsm.13175

Table 1.

Characteristics of studies included in this meta‐analysis

Author Year Country Study design Study period n Mean age Median Age Mean BMI(kg/m2) Median BMI(kg/m2) Disease stage(FIGO) Time of assessment SMI cut‐point (cm2/m2) Prevalence of sarcopenia (%) (based on SMI) Outcome NOS score
Su Hyun Chae 13 2021 Korean RS 2002–2017 82 n.a. 52 n.a. 22.6 I–II Pre‐operation ≤38.73 20.7 PFS, OS 8
Angiolo Gadducci 15 2022 Roma RS 2010–2020 134 n.a. 59 n.a. 22.5 I–IV Pre‐operation <40.1 50.0 PFS, OS 8
Beyan Ataseven 9 2018 Germany RS 2011–2016 323 n.a. 67 n.a. n.a. IIIB–IVB Pre‐operation

<38.5

<39

<41

29.4

33.7

47.1

 OS 9
Holger Bronger 11 2017 Germany RS 2003–2013 105 n.a. 65 25.0 ± 5.4 n.a. III–IV At diagnosis ≤38.5 11.4 PFS, OS 9
S. Allison Staley 20 2020 America RS 2000–2017 201 n.a. 63.6 n.a. 26.9 I–IV Pre‐operation ≤41 63.7 PFS, OS, chemo toxicity 9
Amanika Kumar 17 2016 America RS 2006–2012 296 64.6 ± 10.6 n.a. n.a. n.a. IIIC–IV Pre‐operation <39.0 44.6 PFS, OS 9
I.J.G. Rutten 18 2017 Netherlands RS 2000–2015 216 63.1 ± 0.8 n.a. 24.9 ± 0.3 n.a. III–IV Not specified ≤38.73 32.4 OS 8
I.J.G. Rutten 19 2016 Netherlands RS 2000–2014 123 66.5 ± 0.8 n.a. 25.9 ± 0.5 n.a. II–IV At diagnosis <41.5 50.4 Chemo toxicity, OS 9
Stefanie Aust 10 2015 Austria RS 2004–2012 140 60 ± 13 n.a. 24.9 ± 4.8 n.a. I–IV Pre‐operation <41 28.9 PFS, OS 9
Chueh‐Yi Huang 2 2020 Taiwan RS 2008–2017 147 54.5 ± 10.5 n.a. 22.3 ± 3.3 n.a. IIIA–IIIB Pre‐operation <39.1 34.1 PFS, OS 7
Se Ik Kim 16 2020 Korean RS 2010–2017 179 57.5 ± 10.6 n.a. 23.6 ± 3.2 n.a. IIIA–IVB Pre‐treatment <39 42.5 PFS, OS 8
Maria Del Grande 14 2021 Switzerland RS 2011–2020 69 65 ± 11.45 n.a. 24.9 ± 6.1 n.a. IB–IV At diagnosis <41 29.0 Chemo toxicity, OS 9
Karine de Aguiar Bruno 12 2021 Brazil RS 2008–2017 239 56.3 ± 11.4 n.a. n.a. n.a. I–IV Pre‐treatment <38.9 35.1 Chemo toxicity, OS 9

BMI, body mass index; FIGO, International Federation for Gynecologic Oncology; n.a., not applicable; NOS, Newcastle–Ottawa Scale; OS, overall survival; PFS, progression−free survival; RS, retrospective; SMI, skeletal muscle index.